Results 41 to 50 of about 224,020 (260)

Gut microbiome and aging—A dynamic interplay of microbes, metabolites, and the immune system

FEBS Letters, EarlyView.
Age‐dependent shifts in microbial communities engender shifts in microbial metabolite profiles. These in turn drive shifts in barrier surface permeability of the gut and brain and induce immune activation. When paired with preexisting age‐related chronic inflammation this increases the risk of neuroinflammation and neurodegenerative diseases.
Aaron Mehl, Eran Blacher
wiley   +1 more source

Cystic craniopharyngioma: intratumoral chemotherapy with alpha interferon

Arquivos de Neuro-Psiquiatria, 2011
OBJECTIVE: To assess whether the cystic craniopharyngiomas can be controlled with the use of intratumoral applications of interferon alpha. METHOD: Nineteen patients with the diagnosis of cystic craniopharyngioma were treated with intratumoral ...
Patrícia Alessandra Dastoli, Jardel Mendonça Nicácio, Nasjla Saba Silva, Andrea Maria Capellano, Silvia R.C. Toledo, Daniela Ierardi, Sérgio Cavalheiro   +6 more
doaj   +1 more source

Modeling hepatic fibrosis in TP53 knockout iPSC‐derived human liver organoids

Molecular Oncology, EarlyView.
This study developed iPSC‐derived human liver organoids with TP53 gene knockout to model human liver fibrosis. These organoids showed elevated myofibroblast activation, early disease markers, and advanced fibrotic hallmarks. The use of profibrotic differentiation medium further amplified the fibrotic signature seen in the organoids.
Mustafa Karabicici, Soheil Akbari, Ceyda Caliskan, Canan Celiker, Ozden Oz, Leman Binokay, Gökhan Karakulah, Serif Senturk, Esra Erdal   +8 more
wiley   +1 more source

Some biological properties of the human amniotic membrane interferon

Memorias do Instituto Oswaldo Cruz, 1992
Human amniotic interferon was investigated to define the species specificity of its antiviral action and compare its anti-cellular and NK cell stimulating activities with those of other human interferons.
P. C. P. Ferreira, L. de la Roque, V. M. Rumjanek, R. R. Golgher   +3 more
doaj   +1 more source

SEVERE OSTEOPOROSIS DUE TO SYSTEMIC MAST CELL DISEASE: SUCCESSFUL TREATMENT WITH INTERFERON ALPHA-2B [PDF]

, 2017
We describe a 33-yr-old man suffering from severe vertebral osteoporosis and urticaria pigmentosa due to systemic mast cell disease (SMCD). Because i.v.
BEYELER, C., DAHINDEN, C., GERBER, N. J., HUNZIKER, T., LEHMANN, T., LÄMMLE, B., OLAH, A. J., VOCK, P.   +7 more
core  

Rapid decrease in titer and breadth of neutralizing anti-HCV antibodies in HIV/HCV-coinfected patients who achieved SVR [PDF]

, 2019
The main targets for neutralizing anti-hepatitis C virus (HCV) antibodies (HCV-nAbs) are the E1 and E2 envelope glycoproteins. We have studied the characteristics of HCV-nAbs through a retrospective study involving 29 HIV/HCV-coinfected patients who ...
Berenguer, Juan, Carrero, Ana, Crespo, Manuel, González García, Juan, Guardional, Josep M., Gómez, Julián, Jiménez Sousa, María Angeles, Martínez, Isidoro, Resino, Salvador, Santos, Ignacio de los, The GESIDA 3603b Cohort Study Group, Vigón, Lorena, Von Wichmann, Miguel A., Vázquez Morón, Sonia, Yélamos, María Belén   +14 more
core   +4 more sources

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source

Experience with pegylated interferon α-2a in advanced myeloproliferative neoplasms in an international cohort of 118 patients

Haematologica, 2012
The Philadelphia negative myeloproliferative neoplasms, including polycythemia vera, essential thrombocythemia, and myelofibrosis, are associated with substantial vascular and transformative complications.
Krisstina Gowin, Prakash Thapaliya, Jan Samuelson, Claire Harrison, Deepti Radia, Bjorn Andreasson, John Mascarenhas, Alessandro Rambaldi, Tiziano Barbui, Catherine J. Rea, John Camoriano, Amy Gentry, Jean-Jacques Kiladjian, Casey O'Connell, Ruben Mesa   +14 more
doaj   +1 more source

Effect of a genetically engineered interferon-alpha versus traditional interferon-alpha in the treatment of moderate-to-severe COVID-19: a randomised clinical trial

Annals of Medicine, 2021
Background There are few effective therapies for coronavirus disease 2019 (COVID-19) upon the outbreak of the pandemic. To compare the effectiveness of a novel genetically engineered recombinant super-compound interferon (rSIFN-co) with traditional ...
Chuan Li, Fengming Luo, Chengwu Liu, Nian Xiong, Zhihua Xu, Wei Zhang, Ming Yang, Ye Wang, Dan Liu, Chao Yu, Jia Zeng, Li Zhang, Duo Li, Yanbin Liu, Mei Feng, Ruoyang Liu, Jiandong Mei, Senyi Deng, Zhen Zeng, Yuanhong He, Haiyan Liu, Zhengyu Shi, Meng Duan, Deying Kang, Jiayu Liao, Weimin Li, Lunxu Liu   +26 more
doaj   +1 more source

Modulation of interferon-[alpha] secretion by activated platelets in systemic lupus erythematosus. [PDF]

, 2008
Type I interferons play a key role in systemic lupus erythematosus (SLE) pathogenesis as an "IFN signature" is found in the majority of patients with active SLE.
Bernard Weill, Carole Nicco, Fré, Jean-Franç, Jean-Franç, Jean-Luc Pellegrin, Julien Seneschal, Patrick Blanco, Pierre Duffau   +8 more
core   +1 more source